Skip to main content
. 2020 Feb 12;9(1):1726168. doi: 10.1080/2162402X.2020.1726168

Figure 1.

Figure 1.

Development of a novel hTERT promoter-regulated oncolytic HSV-1 virus (OVH) with selective oncolytic capability. (A) Schematic diagram of KOS and KOS-derived HSV-1 recombinant constructs (dICP0, OVN and OVH) used in this study. (B) Western blot analysis of ICP0 and ICP34.5 expression in various infected U-2 OS cells 48 h after virus infection. (C-D) Western blot analysis of ICP27 and ICP4 expression in various infected human normal cell lines (HUVECs, L-02 and HEL299) (C) and human tumor cell lines (MCF-7, Hep3B and H1299) (D) 3 h, 6 h, and 9 h after virus infection. (E) Viral replication assays were performed on various infected cell lines (MOI = 1 PFU/cell). Viruses harvested from infected cells 48 h after virus infection were titrated. Fold changes between groups were calculated and shown. (F) Cell viability was measured in various infected cell lines 72 h after virus infection (MOI = 1 PFU/cell). Remaining cells harvested from individual virus infected cells were measured by trypan blue exclusion method. Values are means of three independent experiments, data are shown as means ± SEM. *P < .05, ***P < .001, ****P < .0001, ns, not significant by one-way ANOVA test for F.